Theodore Alan Huizenga Sells 1,632 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Theodore Alan Huizenga sold 1,632 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $37,209.60. Following the transaction, the chief accounting officer owned 48,670 shares in the company, valued at $1,109,676. This represents a 3.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Theodore Alan Huizenga also recently made the following trade(s):

• On Monday, December 29th, Theodore Alan Huizenga sold 85 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $34.38, for a total transaction of $2,922.30.

Ultragenyx Pharmaceutical Stock Down 1.2%

Shares of Ultragenyx Pharmaceutical stock opened at $21.80 on Thursday. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.41 and a twelve month high of $42.37. The company’s 50 day moving average is $23.56 and its 200 day moving average is $29.19. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -3.73 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The company had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.39) earnings per share. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on RARE shares. Guggenheim reduced their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Truist Financial dropped their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. HC Wainwright reduced their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Wells Fargo & Company decreased their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th. Finally, Wedbush reiterated a “neutral” rating and set a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $68.29.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Institutional support remains in the register, which can help stabilize the float and provide long‑term demand for shares. Read More.
• Neutral Sentiment: Analyst coverage is still skewed toward buys and the company recently reported revenue beat but an EPS miss (Feb. 12). That mixed fundamental backdrop leaves the stock sensitive to news and revisions.
• Negative Sentiment: Legal overhang: multiple law firms have circulated investor notices and a securities class action has been filed alleging misstatements/omissions related to setrusumab; the lead‑plaintiff deadline (Apr. 6, 2026) concentrates attention on potential damages and litigation risk. Read More.
• Negative Sentiment: Regulatory/program risk amplified: Levi & Korsinsky highlights that RARE plunged ~42% after disclosure of a Phase III failure for setrusumab — that clinical setback remains the root cause of the stock’s heightened volatility and underpins many of the litigation claims. Read More.
• Negative Sentiment: Clustered insider selling: the CEO and several senior executives and officers disclosed large share sales (multiple filings show material blocks around $22.7–22.8), which often weighs on near‑term sentiment and raises questions for some investors. Read More.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently modified their holdings of the company. Assetmark Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank increased its holdings in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares during the last quarter. Danske Bank A S purchased a new stake in Ultragenyx Pharmaceutical in the 3rd quarter worth $39,000. Smartleaf Asset Management LLC lifted its stake in Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Covestor Ltd boosted its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.